Peer-review started: December 5, 2022
First decision: January 17, 2023
Revised: January 18, 2023
Accepted: February 21, 2023
Article in press: February 21, 2023
Published online: March 14, 2023
Processing time: 94 Days and 19.5 Hours
Melatonin is widely available as a supplement, usually for sleep disorders. The consumption of melatonin supplements has increased considerably in recent years. An overlooked aspect of melatonin’s administration is the resulting increase in prolactin secretion, via its action on hypothalamic dopaminergic neurons. We believe that since the effect of melatonin on prolactin is tangible, the laboratory finding of hyperprolactinemia could be encountered more often, given the increase in melatonin’s use. This is an issue that merits further study.
Core Tip: Melatonin, although being an active hormone, is widely available as a supplement. The consumption of melatonin supplements has increased considerably in recent years. Melatonin may increase prolactin. The laboratory finding of hyperprolactinemia could be encountered more often, given the increase in melatonin’s use.
- Citation: Venaki E, Koukkou E, Ilias I. Melatonin’s actions are not limited to sleep. World J Exp Med 2023; 13(2): 4-6
- URL: https://www.wjgnet.com/2220-315X/full/v13/i2/4.htm
- DOI: https://dx.doi.org/10.5493/wjem.v13.i2.4
Melatonin, although being an active hormone, is widely available as a supplement[1-3]. It is taken to treat sleep disorders/insomnia, for adults usually at doses ranging from 0.5 to 6.0 mg at bedtime, with reported various degrees of effectiveness[4]. Other potential beneficial effects of melatonin include the prevention of delirium in hospitalized patients and - still at the experimental stage - restorative action on the cirrhotic liver[5,6]. Very recently, melatonin, given at 5.0 mg at bedtime in healthy older adults was considered to be effective in increasing sleep time and efficiency[7].
The consumption of melatonin supplements has increased considerably in recent years, as shown in studies in the United Kingdom and the United States[1,2]. In the United States, in the years 1999-2000, 0.4% of the population were taking melatonin, whereas in 2017-2018, this percentage rose to 2.1%[1]. An overlooked aspect of melatonin’s administration is the resulting increase in prolactin secretion, via its action on hypothalamic dopaminergic neurons[8,9]. The relevant studies date to the previous century and in the most recent ones, melatonin given at a dose of up to 5 mg at bedtime quadrupled acutely prolactin levels compared to baseline[8,9].
Hyperprolactinemia is not uncommon, especially in women with polycystic ovaries syndrome, pituitary adenomas, hypothyroidism, macroprolactinemia, or therapy with hyperprolactinemia-inducing medications[10]. Interestingly, and despite the known action of melatonin on prolactin, melatonin use is not usually included among the drug-induced causes of hyperprolactinemia[11].
Based on the above, we believe that since the effect of melatonin on prolactin is tangible, the laboratory finding of hyperprolactinemia could be encountered more often, given the increase in melatonin’s use. This issue merits further study, because the caveat is that the available literature has honed on acute effects of melatonin on prolactin. Thus, the effects of chronic use of melatonin on prolactin are obscure. These could be assessed initially in a simple manner: In subjects with hyperprolactinemia, medical history could query on the administration of melatonin. A further step could be a prospective study in subjects that commence melatonin supplementation.
Provenance and peer review: Unsolicited article; Externally peer reviewed.
Peer-review model: Single blind
Corresponding Author’s Membership in Professional Societies: Hellenic Endocrine Society - Athens Medical Association, 79438.
Specialty type: Medicine, research and experimental
Country/Territory of origin: Greece
Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): B, B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0
P-Reviewer: Byeon H, South Korea; Menendez-Menendez J, Spain; Oprea VD, Romania S-Editor: Wang JJ L-Editor: A P-Editor: Wang JJ
1. | Li J, Somers VK, Xu H, Lopez-Jimenez F, Covassin N. Trends in Use of Melatonin Supplements Among US Adults, 1999-2018. JAMA. 2022;327:483-485. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 23] [Cited by in F6Publishing: 47] [Article Influence: 23.5] [Reference Citation Analysis (0)] |
2. | Wan M, Begum R, Rashed AN. Trends, geographical variation and factors associated with melatonin prescribing in general practices in England: A practice-level analysis. Br J Clin Pharmacol. 2022;88:2430-2436. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
3. | Grigg-Damberger MM, Ianakieva D. Poor Quality Control of Over-the-Counter Melatonin: What They Say Is Often Not What You Get. J Clin Sleep Med. 2017;13:163-165. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis (0)] |
4. | Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8:e63773. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 250] [Cited by in F6Publishing: 261] [Article Influence: 23.7] [Reference Citation Analysis (0)] |
5. | Colares JR, Hartmann RM, Schemitt EG, Fonseca SRB, Brasil MS, Picada JN, Dias AS, Bueno AF, Marroni CA, Marroni NP. Melatonin prevents oxidative stress, inflammatory activity, and DNA damage in cirrhotic rats. World J Gastroenterol. 2022;28:348-364. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis (0)] |
6. | You W, Fan XY, Lei C, Nie CC, Chen Y, Wang XL. Melatonin intervention to prevent delirium in hospitalized patients: A meta-analysis. World J Clin Cases. 2022;10:3773-3786. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis (4)] |
7. | Duffy JF, Wang W, Ronda JM, Czeisler CA. High dose melatonin increases sleep duration during nighttime and daytime sleep episodes in older adults. J Pineal Res. 2022;73:e12801. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis (0)] |
8. | Forsling ML, Wheeler MJ, Williams AJ. The effect of melatonin administration on pituitary hormone secretion in man. Clin Endocrinol (Oxf). 1999;51:637-642. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 1.6] [Reference Citation Analysis (0)] |
9. | Kostoglou-Athanassiou I, Treacher DF, Wheeler MJ, Forsling ML. Melatonin administration and pituitary hormone secretion. Clin Endocrinol (Oxf). 1998;48:31-37. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 1.6] [Reference Citation Analysis (0)] |
10. | Lau CS, Aw TC. A Current Approach to Hyperprolactinemia. Int Arch Endocrinol Clin Res. 2019;5:018. [DOI] [Cited in This Article: ] |
11. | Vilar L, Vilar CF, Lyra R, Freitas MDC. Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia. Neuroendocrinology. 2019;109:7-19. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 46] [Cited by in F6Publishing: 62] [Article Influence: 12.4] [Reference Citation Analysis (0)] |